A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

BACKGROUND: Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to improve l...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Immunother Cancer
Huvudupphovsmän: Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2018
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6062934/
https://ncbi.nlm.nih.gov/pubmed/30053905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0387-x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk